|
|
Tg Therapeutics inc (TGTX) |
|
Price: $8.7700
$-0.05 
-0.567%
|
| Day's High:
| $8.86
| Week Perf:
| -4.05 %
|
| Day's Low: |
$ 8.55 |
30 Day Perf: |
-16.16 % |
| Volume (M): |
2,218 |
52 Wk High: |
$ 35.67 |
| Volume (M$): |
$ 19,454 |
52 Wk Avg: |
$15.54 |
| Open: |
$8.82 |
52 Wk Low: |
$4.86 |
|
|
| Market Capitalization (Millions $) |
1,241 |
| Shares
Outstanding (Millions) |
142 |
| Employees |
132 |
| Revenues (TTM) (Millions $) |
24 |
| Net Income (TTM) (Millions $) |
-176 |
| Cash Flow (TTM) (Millions $) |
-50 |
| Capital Exp. (TTM) (Millions $) |
0 |
Tg Therapeutics Inc
TG Therapeutics Inc. is a publicly-traded biopharmaceutical company based in New York City, focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. The company's pipeline consists of multiple product candidates, including small molecule inhibitors and monoclonal antibodies.
One of the company's most advanced product candidates is umbralisib, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase-1 epsilon (CK1') that is being evaluated in clinical trials for the treatment of hematologic malignancies and solid tumors. The drug has demonstrated promising anti-tumor activity in early-phase studies and is currently in phase III development for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
TG Therapeutics also has a pipeline of monoclonal antibodies targeting B-cell-specific proteins, including ublituximab, a glycoengineered anti-CD20 monoclonal antibody that targets the same protein as rituximab but has greater efficacy and reduced side effects. This drug, in combination with umbralisib, has shown potential in a phase III clinical trial for relapsed or refractory CLL/SLL.
The company's other product candidates include TG-1501, a monoclonal antibody that targets a B-cell receptor signaling protein, and TG-1701, a next-generation BTK inhibitor that is in preclinical development.
TG Therapeutics is also exploring the potential of its product candidates in other indications, such as multiple sclerosis and inflammatory bowel disease.
In addition to its drug development efforts, TG Therapeutics has also entered into partnerships and collaborations with other companies, academic institutions, and research organizations to advance the development of its product candidates and expand its pipeline.
Overall, TG Therapeutics is a cutting-edge biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. With a strong pipeline of product candidates and ongoing clinical trials, the company has the potential to make a significant impact on patient outcomes in these therapeutic areas.
Company Address: 3020 Carrington Mill Blvd, Suite 475 Morrisville 27560 NC
Company Phone Number: 554-4484 Stock Exchange / Ticker: NASDAQ TGTX
| TGTX is expected to report next financial results on November 08, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Immuron Limited
In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.
|
|
Procyon Corporation
Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.
|
|
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.
|
|
Palatin Technologies Inc
Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
|
|
Ibio Inc
In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.26 $ |
| Revenues (TTM) |
0.17 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.02 $
|
| Book Value |
0.29 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.26 $
|
| Revenues (TTM) |
0.17 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.02 $
|
| Book Value |
0.29 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
